MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice

Figure 1 Serum active glucagon-like peptide-1 concentrations, body weight, food intake or ratio of liver weight to body weight in ob/ob mice and their lean littermates. A: Serum active glucagon-like peptide-1 (GLP-1) concentrations (pg/mL) in ob/ob mice that were fed either a normal chow diet (ob/ob) or a normal chow diet supplemented with MK-0626 (1.5 mg/kg) (ob/ob + MK 1.5) or MK-0626 (3 mg/kg) (ob/ob + MK 3.0) and their lean littermates fed a normal chow diet (lean). Serum samples were collected at the end of the 8-wk treatment period; B: Changes in body weight in lean, ob/ob, ob/ob + MK 1.5 and ob/ob + MK 3.0 groups during the treatment; C: Changes in food intake in lean, ob/ob, ob/ob + MK 1.5 and ob/ob + MK 3.0 groups during the treatment; D: A comparison of body weight at the end of the 8-wk treatment period; E: A comparison of food intake at the end of the 8-wk treatment period; F: A comparison of the ratio of liver weight to body weight at the end of the 8-wk treatment period. ^bP < 0.01 vs the lean group; ^cP < 0.05, ^dP < 0.01 vs the ob/ob group (n = 16 mice per group).